Orion Corporation converts 337,000 A shares into B shares.
PorAinvest
miércoles, 20 de agosto de 2025, 2:21 am ET1 min de lectura
OEC--
The total number of shares in Orion Corporation has increased to 141,134,278, comprising 31,971,783 A shares and 109,162,495 B shares. The total number of votes has also increased to 748,598,155 following the conversion [1].
Orion Corporation, a globally operating Nordic pharmaceutical company, has a portfolio that includes proprietary and generic medicines, as well as consumer health products. The company's core therapy areas are oncology and pain, with products used to treat cancer, neurological diseases, and respiratory conditions. In 2024, Orion's net sales amounted to EUR 1,542 million, with approximately 3,700 professionals employed worldwide [1].
The conversion of shares aligns with Orion's strategic goals and is aimed at optimizing its share structure and capitalization. The company's A and B shares are listed on Nasdaq Helsinki.
References:
[1] https://finance.yahoo.com/news/337-000-orion-corporation-shares-060000092.html
Orion Corporation has converted 337,000 A shares into 337,000 B shares, increasing the total number of shares to 141,134,278. The number of A shares is now 31,971,783, and the number of B shares is 109,162,495. The total number of votes has increased to 748,598,155. This conversion was made in accordance with Orion's Articles of Association.
Orion Corporation has announced a significant change in its share structure, converting 337,000 A shares into B shares. This conversion, executed in accordance with the company's Articles of Association, has been entered into the Trade Register on August 20, 2025 [1].The total number of shares in Orion Corporation has increased to 141,134,278, comprising 31,971,783 A shares and 109,162,495 B shares. The total number of votes has also increased to 748,598,155 following the conversion [1].
Orion Corporation, a globally operating Nordic pharmaceutical company, has a portfolio that includes proprietary and generic medicines, as well as consumer health products. The company's core therapy areas are oncology and pain, with products used to treat cancer, neurological diseases, and respiratory conditions. In 2024, Orion's net sales amounted to EUR 1,542 million, with approximately 3,700 professionals employed worldwide [1].
The conversion of shares aligns with Orion's strategic goals and is aimed at optimizing its share structure and capitalization. The company's A and B shares are listed on Nasdaq Helsinki.
References:
[1] https://finance.yahoo.com/news/337-000-orion-corporation-shares-060000092.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios